Platelet receptors as therapeutic targets: Past, present and future

被引：62
|
作者：
Jamasbi, Janina [1 ]
Ayabe, Keng [2 ]
Goto, Shinya [2 ]
Nieswandt, Bernhard [3 ,4 ]
Peter, Karlheinz [5 ]
Siess, Wolfgang [1 ,6 ]
机构：
[1] Ludwig Maximilians Univ Munchen, Inst Prevent Cardiovasc Dis, Munich, Germany
[2] Tokai Univ, Sch Med, Dept Med Cardiol, Isehara, Kanagawa, Japan
[3] Univ Wurzburg, Univ Hosp, Expt Biomed, Wurzburg, Germany
[4] Univ Wurzburg, Rudolf Virchow Ctr, Wurzburg, Germany
[5] Baker IDI Heart & Diabet Inst, Atherothrombosis & Vasc Biol, Melbourne, Vic, Australia
[6] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany
来源：
THROMBOSIS AND HAEMOSTASIS | 2017年 / 117卷 / 07期
基金：
英国医学研究理事会;
关键词：
Antiplatelet agents; GP Ib alpha; GP VI; GP IIb/IIIa; PAR-1; VON-WILLEBRAND-FACTOR; ACUTE CORONARY SYNDROMES; INDUCED THROMBUS FORMATION; INTIMA-MEDIA THICKNESS; GLYCOPROTEIN IB-ALPHA; ANTI-GPVI ANTIBODIES; CONTROLLED PHASE-II; IN-VIVO; ANTIPLATELET THERAPY; MONOCLONAL-ANTIBODY;
D O I：
10.1160/TH16-12-0911
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anti-platelet drugs reduce arterial thrombosis after plaque rupture and erosion, prevent stent thrombosis and are used to prevent and treat myocardial infarction and ischaemic stroke. Some of them may also be helpful in treating less frequent diseases such as thrombotic thrombocytopenic purpura. The present concise review aims to cover current and future developments of anti-platelet drugs interfering with the interaction of von Willebrand factor (VWF) with glycoprotein (GP) Ib alpha, and directed against GPVI, GPIIb/IIIa (integrin alpha(IIb)beta(3)), the thrombin receptor PAR-1, and the ADP receptor P2Y(12). The high expectations of having novel antiplatelet drugs which selectively inhibit arterial thrombosis without interfering with normal haemostasis could possibly be met in the near future.
引用
收藏
页码：1249 / 1257
页数：9
相关论文
共 50 条
  • [1] Therapeutic Targets in Sepsis: Past, Present, and Future
    Seeley, Eric J.
    Bernard, Gordon R.
    CLINICS IN CHEST MEDICINE, 2016, 37 (02) : 181 - 189
  • [2] Platelet preservation: Past, present, and future
    Ohto, Hitoshi
    TRANSFUSION AND APHERESIS SCIENCE, 2011, 44 (03) : 269 - 269
  • [3] Platelet Concentrates: Past, Present and Future
    Prakash S.
    Thakur A.
    Journal of Maxillofacial and Oral Surgery, 2011, 10 (1) : 45 - 49
  • [4] Opioid receptors: Past, present, and future
    Prisinzano, Thomas E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [5] OPIOID RECEPTORS - PAST, PRESENT AND FUTURE
    MANSOUR, A
    WATSON, SJ
    AKIL, H
    TRENDS IN NEUROSCIENCES, 1995, 18 (02) : 69 - 70
  • [6] Therapeutic communities: Past, present and future
    Birch, S
    JOURNAL OF FORENSIC PSYCHIATRY, 2000, 11 (01): : 249 - 251
  • [7] Therapeutic communities: Past, present and future
    Rawlings, B
    SOCIOLOGY-THE JOURNAL OF THE BRITISH SOCIOLOGICAL ASSOCIATION, 2000, 34 (03): : 590 - 591
  • [8] Therapeutic training: past, present and future
    Ametov, A. S.
    Valitov, B. I.
    Chernikova, N. A.
    DIABETES MELLITUS, 2012, 15 (01): : 71 - 77
  • [9] Therapeutic communities: Past, present, and future
    Francell, EG
    Griffin-Francell, C
    PSYCHIATRIC SERVICES, 2001, 52 (06) : 850 - 851
  • [10] Therapeutic communities: Past, present and future
    Pilgrim, D
    SOCIAL POLICY & ADMINISTRATION, 2000, 34 (02) : 228 - 230
12345